Cargando…
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective
Immuno-oncologics (IOs) differ from chemotherapies as they prime the patient’s immune system to attack the tumor, rather than directly destroying cancer cells. The IO mechanism of action leads to durable responses and prolonged survival in some patients. However, providing robust evidence of the lon...
Autores principales: | Quinn, Casey, Garrison, Louis P, Pownell, Anja K, Atkins, Michael B, de Pouvourville, Gérard, Harrington, Kevin, Ascierto, Paolo Antonio, McEwan, Phil, Wagner, Samuel, Borrill, John, Wu, Elise |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359062/ https://www.ncbi.nlm.nih.gov/pubmed/32661115 http://dx.doi.org/10.1136/jitc-2020-000648 |
Ejemplares similares
-
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies
por: Atkins, Michael B, et al.
Publicado: (2023) -
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
por: Rini, Brian I., et al.
Publicado: (2016) -
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
por: Rini, Brian I., et al.
Publicado: (2019) -
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
por: Atkins, Michael B, et al.
Publicado: (2022) -
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response
por: Arnaldez, Fernanda I, et al.
Publicado: (2020)